Home / Explore Insights / Using FDA’s Draft Guidance on Risk-Based Monitoring to Improve Clinical Data Quality
/ Insights / Explore Insights / Using Fdas Draft Guidance On Risk Based Monitoring To Improve Clinical Data Quality
King L, Woolson R Clinical Trial Oversight Summit None 06/02/2013 Presentation
You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team,
Picture this: a complex trial is running, but it has been plagued with issues from the start.
ICH E6(R3) is here, and with it, clinical teams are bracing for the impacts. Biotechs are being
Behind every enrollment milestone is a web of relationships—some strong, some strained, and some that make all
Every CRO claims to value sites. But the true nature of their site relationships could determine the
